Exploring the Technology
of Tomorrow

Capstan Medical is commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, Capstan Medical pioneered a patient-optimized approach to repair and replace heart valves. Biofund is a seed stage investor.

Dystrogen Therapeutics is a clinical-stage chimeric cell therapy company focusing on rare diseases. The company is currently testing in humans the Dystrophic Expressing Chimeric (DEC) cell therapy for Duchenne Muscular Dystrophy – a terminal illness that affects young boys and lead the gradually worsening dysfunction of the muscular system.

Dystrogen Gene Therapies is a life sciences company focused on the development of therapies for rare genetic neurodegenerative disorders. Our currently most advanced therapeutic candidate is for Huntington’s Disease (HD) and has produced a series of highly promising pre-clinical data.

Holo Surgical Inc. is a company focused on computer-assisted surgery, that has developed an FDA-certified, Artificial Intelligence and Augmented Reality based surgery guidance system, that helps doctors (and later robots) perform medical procedures more precisely, safer, and faster.

Labtronic is a robotic company developing autonomous laboratory solutions

Medicalgorithmics (MDG) is a medical technology company focusing on cardiology. The company has a number of AI based, FDA cleared software algorithms and medical devices. As of 2022, the company performed 170,000 annual cardiac tests worldwide. Biofund is the major owner of MDG, which is publicly traded.

The BISHEP intracanal system is Robotron’s robotic-assisted platform for endoscopic spinal decompression, designed to be a safe and effective tissue-preserving alternative to spinal laminectomy.

Inteneural Networks has developed cutting-edge, AI- and Machine Learning based medical applications that help in brain diagnosis and produce in minutes what would take experienced neuroradiologists hours or days of work.  These applications can detect even hard to identify potential problems that are likely to be missed by human doctors.  INN can revolutionize the field of neuroscience and lead to improved patient outcomes.

Kardiolytics has the goal to make advanced, highly accurate diagnostics of the heart – inexpensive and widely available, including the parts of the world that currently have limited access to advanced medical diagnostics.  The Kardiolytics technology uses Artificial Intelligence to derive from inexpensive and widely available CT scans of the heart – crucial diagnostic information about narrowing of blood vessels, that normally can be obtained only by applying complex, expensive, and highly invasive procedures that involve inserting probes into the heart.